Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | SELL | P14151 | 2/20 | 0.58 |
| ▸ | SELP | P16109 | 2/20 | 0.58 |
| ▸ | SELE | P16581 | 2/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18877325 | 0.83 | KMT2A (0.65) | KMT2ASELLSELPSELETPSAB1 | |
| SCHEMBL417953 | 0.82 | AOC3 (0.72) | KMT2ACA1CA2TPSAB1AOC3 | |
| SCHEMBL23571643 | 0.82 | TPSAB1 (0.81) | CA1CA2TPSAB1AOC3 | |
| SCHEMBL27617137 | 0.82 | CA2 (0.62) | KMT2ACA1CA2 | |
| SCHEMBL18362094 | 0.81 | KMT2A (0.68) | KMT2ASELLSELPSELENR1H4 | |
| SCHEMBL13884075 | 0.81 | CA2 (0.60) | KMT2ACA1CA2TPSAB1NR1H4 | |
| SCHEMBL21781874 | 0.81 | CA1 (0.64) | CA1CA2TPSAB1EPHX2AOC3 | |
| SCHEMBL15808530 | 0.81 | CA2 (0.64) | CA1CA2TPSAB1AOC3 | |
| Hydrochloric Acid SCHEMBL12478237 | 0.81 | AOC3 (0.73) | KMT2ACA1CA2TPSAB1AOC3 | |
| Bromide SCHEMBL10352605 | 0.81 | AOC3 (0.70) | KMT2ACA1CA2TPSAB1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120177571-A1 | PANCREATIC ENDOCRINE CELL INDICATING AGENT AND UTILIZATION OF SAME | RIKEN (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2460542-A1 | PANCREATIC ENDOCRINE CELL INDICATOR AND UTILIZATION OF SAME | Riken (JP) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011034078-A1 | GLYCINE COMPOUND | アステラス製薬株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
| WO-2009055002-A1 | COMBINED INHIBITORS OF CYCLOOXYGENASE AND SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) (VASCULAR ADHESION PROTEIN, VAP-1) | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184520-A1 | GLYCINE COMPOUND | SLC5A1, AQP1, VAPB | KMT2A 4626/4885CA1 3593/4885CA2 1550/4885 |
| US-20120177571-A1 | PANCREATIC ENDOCRINE CELL INDICATING AGENT AND UTILIZATION OF SAME | IAPP, SSTR4, SSTR1 | KMT2A 2940/4885CA1 167/4885CA2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.